What are IBRX's recent SEC filings?
8-K · Fda ApprovalOct 14, 2026
ImmunityBio announced that the FDA expanded the approved indication for ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with BCG to include patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only tumors.
View full filing details →Has IBRX ever done a stock split?
No stock splits are recorded for IBRX.
What is IBRX's share float?
Public Float
$83.3M
Shares Outstanding
$1.1B
Free Float %
785.6%
Get Real-Time IBRX Intelligence
SEPT X-Ray combines SEC filings with price targets, support/resistance levels, and smart money tracking — updated every 30 minutes.
Try SEPT X-Ray Free